AI-Driven Precision Diagnostic System for Lung Cancer Based on Liquid Biopsy
NCT ID: NCT07009769
Last Updated: 2025-06-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
865 participants
OBSERVATIONAL
2024-10-16
2025-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Liquid Biopsy in Lung Cancer
NCT03479099
Clinical Evaluation of the Lung Cancer AI-based Decision Support Tool in Low-Dose Lung CT
NCT07052773
Construction and Evaluation of the Liquid Biopsy-based Early Diagnostic Model for Lung Cancer
NCT04156360
Lung Cancer Screening by Artificial Intelligence Device
NCT06295497
Cell Free DNA for the Diagnosis and Treatment in Early NSCLC
NCT03791034
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥ 30 years
* Lung cancer based on radiologic and/or histopathologic examination
* No prior diagnosis of any other cancer and no history of anticancer treatment before the date of blood sample collection
* Republic of Korea nationality
* No history of any cancer
* Age ≥ 30 years
Exclusion Criteria
* Prior cancer treatment before blood collection
* Incomplete clinical data
* No consent for sample use
* History of any malignancy
* Incomplete clinical information or no consent for sample use
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Korea University Guro Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hyun Koo Kim
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Korea University Guro Hospital
Guro-gu, Seoul, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024GR0131
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.